5AM Ventures | Activity | F4
5AM Ventures Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
Exit
Portfolio company Crinetics Pharmaceuticals agreed to be acquired by Vertex Pharmaceuticals for $10 billion. Crinetics
4 milestones · MAR 2026 – MAY 2026 Show all
Milestone
Portfolio company Arvinas received FDA approval of VEPPANU (vepdegestrant) for advanced breast cancer. Arvinas
Milestone
Portfolio company Reprotech merged with TMRW Life Sciences to create comprehensive technology-enabled fertility cryostorage platform managing 1M+ specimens. Reprotech
Milestone
Independent Data Monitoring Committee recommended initiation of Cohort 2 in Entrada's ELEVATE-44-201 gene therapy trial at increased dose. Entrada Therapeutics
Milestone
Portal Instruments signed multi-million dollar development agreement to advance PRIME NEXUS large volume reusable autoinjector to clinical readiness. Portal Instruments
Exit
Portfolio company Wildcat Discovery Technologies acquired by Swedish battery technology firm Holyvolt for $73M. Wildcat Discovery Technologies
Milestone
NodThera appointed Geoff McDonough, M.D. as Chief Executive Officer. NodThera
3 investments · JAN 2026 Show all Investment
Co-led Mendra's $82M Series A alongside OrbiMed and 8VC for rare disease therapeutics using AI. Mendra
Investment
Participated in Precede Biosciences' $83.5M Series B for next-generation precision diagnostics. Precede Biosciences
Investment
Participated in Kinaset Therapeutics' $103M Series B for inhaled therapeutics in respiratory diseases. Kinaset Therapeutics
Milestone
CAMP4 Therapeutics entered a strategic collaboration with GSK to advance RNA-based therapeutic discoveries. CAMP4 Therapeutics
Investment
Co-led ProLynx's $70M Series A for ultra-long-acting obesity medicines. ProLynx
Investment
Participated in Lifordi's $112M financing (including strategic investment from Sanofi) for antibody-drug conjugates in autoimmune disease. Lifordi
Exit
Portfolio company Cidara Therapeutics acquired by Merck for $9.2B for long-acting antiviral flu therapy. Cidara Therapeutics